Key clinical point: Venetoclax-based therapies offered good efficacy with an acceptable toxicity profile in a real-life setting of patients with relapsed/refractory acute myeloid leukemia (AML).
Major finding: During median follow-up of 10.7 months, composite complete remission was achieved in 55% of patients, of which 61% achieved minimal residual disease negativity. Overall survival and event-free survival were 10.7 and 4.5 months, respectively. Grade 4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 100%, 95%, and 45% of patients, respectively.
Study details: Data come from retrospective assessment of 47 patients with relapsed/refractory AML treated with venetoclax in combination with azacytidine, decitabine, or low-dose cytarabine.
Disclosures: This study was supported by a grant from AIRC to the MYNERVA project. The authors declared no conflicts of interest.
Source: Piccini M et al. J Clin Med. 2021 Apr 14. doi: 10.3390/jcm10081684 .